Podcasts about well andrew

(Andrew - Nerf Modding)   In this episode, I had the honour to have Andrew as my guest. He shared with me his interest in Nerf modding as his hobby.   Have you ever looked at an item and thought to yourself… I could improve on that design. Well Andrew does exactly that with Nerf blasters. Sure the original design works great but with a little know how, sprinkle of elbow grease and a whole lot of why not there's multiple ways to modify a Nerf blaster. With the laws of physics in play, how far do you think Andrew can make a Nerf dart fly?   Andrew's link:  Youtube: AndrewG   Time For Your Hobby links: Website: Time For Your Hobby website (click to find Apple, Spotify, Google and more) Merch: TFYHpodcast (on Redbubble) Instagram: @timeforyourhobby Twitter: @tfyhpodcast Podchaser: Time For Your Hobby  Patreon: Timeforyourhobby  Email: timeforyourhobby@gmail.com     If you like this episode and think it can be helpful to someone you are more than welcome to share it and leave a review. If you want to be on my podcast or have any questions at all, by all means, contact me through any of the platforms above. So until the next episode... make some time for your hobby.   Shout out to my Patrons: Chess Talk (https://chesstalk.podbean.com/) Mélissa   Take care,

Well Andrew came over and bumped his gums on my couch and ripped bowls of keef. Anna is 91 years old coming out of the tine. Watch it on YouTube and leave a review please. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/rumble-lips/support

When Andrew came into the studio to record this episode, we have to admit, we were a little more nervous than usual. Why? Because he has his own podcast and therefore he is a pro and we are not. We needn't have worried, we both know Andrew so it was just as relaxed and informal as all our other chats. Here is a link to Andrews own podcast by the way https://www.stitcher.com/podcast/anchor-podcasts/the-tingle-zone-with-andrew-miller you can also find it in the usual places - Apple, Spotify etc etc. So, in this episode we are talking about Andrews career and university journey - he studied a maths degree in France, in French, I mean who does that? So it is fair to say he is pretty good at maths (and French!). So the natural path for someone with amazing mathematical skills would be an accountant right? Well Andrew thought that would be boring so he landed himself a job with KPMG, not knowing anything about them, and became an insolvency practitioner and that is what he did for a large part of his career. Now however, he is a multiple author and business enjoyment guru. You can find out more about the books and Andrews business here https://www.businessenjoyment.com/. Do you might be wondering how the heck he made the switch from an insolvency practitioner in an enormous company to setting up his own business helping people to enjoy theirs and writing books - well listen in to find out! Just as a side note, we both know Andrew because we attend his group sessions called Breathing Spaces (https://www.businessenjoyment.com/breathingspaces) and we will be honest - because that is who we are - we only went to the first one because it was free! But we both loved it and we have been going now for about a year. It is basically a great tool to remind yourself why you are in your business, so you don't get carried away with the financials and stuff and to make sure you actually enjoy it (they are our words, not Andrews). We have met some amazing people through the groups too, people we wouldn't have met otherwise who have enriched our lives - god that sounds so soppy but it is true so we are leaving it in! Anyway, waffling - you should give it a try. Definitely! We hope you enjoy this episode, it is a little longer than usual because we couldn't shut him up! No really, Andrew is a very interesting man - you'll see! https://www.linkedin.com/in/andrewrmiller/ MUSIC FROM OUTSIDER https://www.youtube.com/channel/UCx6iRazzKgr_GyhEriXvJSg PRODUCED BY ABSOLUTE MEDIA (HUDDERSFIELD) http://www.absmedia.co.uk/

Do you ever wake up in the middle of the night in a cold sweat, startled awake from a nightmare that never seems to end? Well Andrew has and that nightmare is Crash Team Racing. Recently this PlayStation classic has been remade and brought to modern gaming platforms and it's still tough as nails, reminding you of gentler times when the worst thing that could happen to you in a race was some squid ink covering your view or a blue shell knocking you down a few ranks. But Drew's slow descent into madness isn't all we talk about this week, oh no! Music in video games is our big topic for the week, with a particular focus on Nobuo Uematsu's contributions to the Final Fantasy series. We also get into what's coming in the newly launched 2nd season of Apex Legends, EA Access's arrival on PlayStation 4, your free games on PlayStation Plus and Xbox Live Gold for the month and so much more. --- Send in a voice message: https://anchor.fm/absentminded/message

This episode is a little bit different, we'll call it "podeutainment", where I teach a guest (and you) all about the mysteries of Podcasting; or at least as good as I know at this point. Andrew Birkett of Atheris Games has been a long time supporter of The Cardboard Herald. Recently, though, he's been making a big impression in board game media through his own coverage, which can be seen in outlets including Casual Game Insider. Well Andrew is embarking on his own podcasting adventure "Games To Glory" with Cody Thompson of Gold Nugget Games, but first he needs to learn how to podcast! Also lookout for upcoming episodes with Andrew and Cody guest hosting TCbH!TIME STAMPS:​​​​​​​00:00:10 - Intro - What's up with this episode?00:03:08 - Games to Glory Podcast00:09:30 - Tip # 1 - Get on twitter / Get involved in communities / Who to follow00:18:12 - Tip # 2 - What kind of mic to get 00:22:10 - Tip # 3 - Sit close to your mic for good sound (with examples!)00:25:55 - Tip # 4 - Gotta get a program to record with00:30:46 - Invitation for listener questions, possible future how-to episodes00:32:17 - Tip # 5 - Manageable Editing / Focus on the core product instead of editing00:37:26 - Tip # 6 - Focus on small, actionable goals and improvements / don't be worried about rough starts00:42:04 - Tip # 7 - What we do for hosting00:46:30 - Atheris rebranding as Atheris Entertainment00:49:55 - Tip # 8 - Where does TCbH's music come from?00:54:01 - Tip # 9 - Most difficult thing about content creation / Sustainability / Being present00:58:30 - Upcoming Atheris Game - Ruins of MarsTotal time - 01:04:20HOT LINKS:Atheris Games - www.atherisentertainment.com/CheapBeats - https://cheapbeatsmusic.bandcamp.comOur Site - www.cardboardherald.comOur Video Channel - https://www.youtube.com/channel/UCsBLZ33CJXoUffCBF7plpjgOur Twitter - https://twitter.com/CardboardHeraldOur Patreon - https://www.patreon.com/user?u=9669551

Good afternoon everyone and welcome to another edition of The Avid Reader. Today our guest is Andrew Santella, author of Soon: An Overdue History of Procrastination, from Leonardo and Darwin to You and Me, published by Del Rey books just last month. Andrew has written for GQ, the NYT Book Review, Slate and Atlantic. He probably could have written more. Soon is a book that will resonate with the vast majority of us. Because most of us are procrastinators. I know Andrew is one because he tells us and because he even postponed this interview and I know I am one because I am reading the last page of his book as I give this introduction. The question is why do we not do what we should be doing and do something else instead or just lay in bed. For instance, while getting ready for this interview, I took off some time to read my email, look at my desk calendar and doodle in the margins, get up to get a sparkling water and rearrange my library. I even checked my bank balance and my Vanguard account, much to my dismay. (I wish I hadn’t). I then ordered new checks. Well Andrew brings us a lot of information and more than a little bit of solace regarding our tendency to put off that which should be done. We get lumped in with such great procrastinators like Charles Darwin, Leonardo Da Vinci Frank Lloyd Wright. Many of these guys and women have done great things while they put off that which they had intended to do. We learn about St. Expedite and his shrine in New Orleans, a shine that we have to wait for since it took so long for Mr. Santella to get there. Even St. Augustine gets into the act.

Good afternoon everyone and welcome to another edition of The Avid Reader. Today our guest is Andrew Santella, author of Soon: An Overdue History of Procrastination, from Leonardo and Darwin to You and Me, published by Del Rey books just last month. Andrew has written for GQ, the NYT Book Review, Slate and Atlantic. He probably could have written more. Soon is a book that will resonate with the vast majority of us. Because most of us are procrastinators. I know Andrew is one because he tells us and because he even postponed this interview and I know I am one because I am reading the last page of his book as I give this introduction. The question is why do we not do what we should be doing and do something else instead or just lay in bed. For instance, while getting ready for this interview, I took off some time to read my email, look at my desk calendar and doodle in the margins, get up to get a sparkling water and rearrange my library. I even checked my bank balance and my Vanguard account, much to my dismay. (I wish I hadn’t). I then ordered new checks. Well Andrew brings us a lot of information and more than a little bit of solace regarding our tendency to put off that which should be done. We get lumped in with such great procrastinators like Charles Darwin, Leonardo Da Vinci Frank Lloyd Wright. Many of these guys and women have done great things while they put off that which they had intended to do. We learn about St. Expedite and his shrine in New Orleans, a shine that we have to wait for since it took so long for Mr. Santella to get there. Even St. Augustine gets into the act.

Originally published September 3, 2015 Mark Highland and I were talking about Bob and I was saying he’s all over Facebook etc these days and since this was definitely one of my all time favorites I thought I’d replay it this week for Valentine’s Day because I love so much but a lot about what he talks about having all sorts of local fruits. Last week I interviewed Jennifer Hill-Hart from  AERO (http://www.aeromt.org)  (Alternative Energy Resource Organization)  and when I mentioned my husband and my’s interest in biodiesel she recommended I get in touch with Bob Quinn. So I reached out to Bob and today he is here to share his story about his organic farm in Big Sandy! The Quinn Organic Farm (http://bobquinnorganicfarmer.com)  in Big Sandy, Montana, within the famed Golden Triangle. The experiments are conducted on small acreage in an effort to determine how a farm family can make a comfortable living on fewer acres. Current experiments include oilseeds for fuel and lubricants, storage and fresh vegetables, crop rotations, green manures, and weed management. Tell us a little about yourself. I was raised here in Big Sandy on the 2400 acre wheat and cattle ranch that my grandfather started in 1920 and my father continued to farm between 1948 – 1978. He was here 30 years. I’ve been here since 1978 with my family, so we’re pushing 40 years here pretty quick. Starting about 1983, I started a flour mill in Fort Benton, with the purpose of marketing our hard red winter wheat and spring wheat crops directly to whole grain bakers in California. We were just selling grain at the beginning. In 1984 we added organic grain that we bought from some organic farmers we found in North East corner of Montana. In 1985 we aded a flour mill. In ’88 we built our own cleaning plant, I had about 10 employees but it was about 50 miles away, so it was always a little bit of a management challenge because I still had my farm, I was farming full time. So finally sold it to an employee Andree Childs in 1999, he has expanded and done much better then I ever did, so I’m happy about that. I started converted to organic about 30 years ago starting experiments in 1985. Planted my first crop in 1986. I had my first 20 acre of certified grain in 1987. I was so excited about our experiments in 3 years transitioned the entire farm in 3 years, and by 1991 we were 100% certified organic and have been that way ever since! That’s gone very well for us. Very excited about it and excited to promote transition organic agriculture around Montana, the US, and around the world!!! That give a little introduction. About the same time in 1985-6 started the ancient grain product we market under the trade mark of KAMUT®. That has grown to the point we now contract with about 150 gardeners in MT, Alberta, Saskatchewan for about 80,000 acres. We sell the grain all over the world. The trademark means it’s always grown organically. Most people who have trouble eating modern wheat, have no trouble eating Kamut brand grain products. This is my son-in-law. How long have you been here? 4 years. Tell the folks if you love it or not. Yeah it’s great! Well I’m Jackie Beyer from the Organic Gardener Podcast Holey Moley Hello Everyone! Well Andrew came to me with an MBA not knowing anything about producing oil, and I said why don’t you try us out for a year, if you don’t like it you can go away with a business creation line on your resume and after 6 months he said he’s having more fun then any of his friends. We supply University of Montana, MSU, Botany Soap, conversation with some other big companies, we also do business with  Organic Valley (http://www.organicvalley.coop) , and a lot of other health food stores as well. Another thing we do is we give back the waste oil and give it back from restaurants and university of food services and we clean... Support this podcast

Show Notes: In the news this week, the 2017 federal budget is out and we go one-on-one with BIOTECanada’s Andrew Casey to find out if it delivers on the promise of an Innovation Agenda, the NRC and the Centre for the Commercialization of Antibodies and Biologics (CCAB) colloborate on an antibody development initiative, and Bellus Health divests itself of Thallion Pharmaceuticals. We have all this and more coming up on Biotechnology Focus Radio. Welcome to another episode of Biotechnology Focus Radio. I’m your host Shawn Lawrence, here to give you a rundown of the week’s top stories on the Canadian biotech scene. Story 1 Our first story this week takes us to Vancouver, where Qu Biologics Inc. reports it has identified immune factors (cytokines and growth factors) in the blood of patients with Crohn’s disease that may predict response to its Site Specific Immunomodulators (SSIs) therapy. According to the company, SSIs are a unique platform of immunotherapies designed to restore the body’s innate immune system. Their discovery was made following further analysis of Qu Biologics recently completed Phase 2 Study in Crohn’s disease. The company says that when combined with patients’ clinical profiles, these biomarkers seemed to coorelate with identifying patients likely to respond to SSI treatment. Dr. Hal Gunn, CEO of Qu Biologics, explained these findings could  mean that patients with Crohn’s disease may now be closer to having precision treatment for their condition for the first time.  In addition, Qu Biologics’ Phase 2 randomized placebo-controlled Crohn’s disease trial results demonstrated that specific blood immune markers associated with immune activation and mucosal healing increased with SSI treatment and SSI response/remission. The company says it plans to initiate a follow-on clinical trial in Crohn’s disease later in 2017 to confirm the value of these blood immune biomarkers in predicting and monitoring response to SSI therapy. Story 2 The National Research Council of Canada (NRC) and Toronto-based Centre for the Commercialization of Antibodies and Biologics (CCAB) are teaming up to advance new innovative therapies discovered out of the University of Toronto. Through this innovative collaboration between government, industry, and academia,  the NRC and the (CCAB) have over the past year already put in place over $1M in collaborative agreements to produce and test therapeutic antibodies discovered at the University. CCAB is a business development and commercialization engine whose mission is to translate UofT’s large portfolio of early stage biologics into high-value assets and products. To this purpose, CCAB has partnered with NRC to biomanufacture and test hundreds of antibodies. With this announcement, the collaboration continues to grow and now leverages NRC’s three programs in Human Health Therapeutics: 1. Biologics and Biomanufacturing: producing biologics, testing their ability to fight solid tumours, and determining their biomanufacturability; 2.  Therapeutics Beyond Brain Barriers: determining if specific antibodies are able to cross the blood-brain barrier, target and fight brain cancer; And 3. Vaccines and Immunotherapeutics: determining if specific antibodies are able to modulate the immune system so that it finds and destroys cancer cells.  As cancer treatment evolves rapidly toward more effective molecules, including single-domain and bi-specific antibodies, antibody-drug conjugates, and immunotherapies, these types of medicines, also called biologics, are able to specifically target cancer cells and in some cases, recruit the body’s immune system to help destroy them. The goal of the collaboration is to identify the most promising antibodies, and increase their value by generating data that effectively de-risks each asset. CCAB says its objective is to then licence lead antibody candidates to seed newly formed Canadian biotechnology companies.  These new Canadian start-ups will, in turn, advance these molecules toward clinical trials in patients.  With several biotechnology companies already participating and benefitting from these programs, the collaboration between CCAB and NRC is clearly set to catalyze the country’s biotech sector and generate promising new cancer treatments for Canadians. Alexion licenses Arbutus’ LNP delivery technology In business news, Alexion Pharmaceuticals has negotiated a license to use Vancouver-based Arbutus Biopharma’s lipid nanoparticle (LNP) delivery technology for one of its rare disease messenger RNA (mRNA) therapeutic candidates. As part of the deal, Arbutus will earn $7.5 million upfront from Alexion and potentially another $75 million in development, regulatory, and commercial milestones, plus single-digit sales royalties. Arbutus will also carry out technology development and provide manufacturing and regulatory support for the Alexion mRNA candidate. Arbutus Biopharma itself is currently focused on developing a cure for chronic hepatitis B virus (HBV) infection. Dr. Mark J. Murray, Arbutus’ President and CEO said this transaction with Alexion illustrates the value of his company’s LNP platform, which he believes has broad potential to deliver mRNA and gene editing therapeutics. He adds that Arbutus is receiving significant interest from companies that require access to the LNP platform to enable their own development programs BELLUS Health sells Thallion Pharmaceuticals subsidiary to Taro Pharmaceuticals BELLUS Health Inc. reports it has entered into a share purchase agreement with Taro Pharmaceuticals Inc. (Taro) for the sale of its wholly-owned subsidiary Thallion Pharmaceuticals Inc. as well as the rights to the drug candidate Shigamab™. According to Bellus, the asset, Shigamab™, is a monoclonal antibody therapy being developed for the treatment of Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (STEC) (sHUS), a rare disease which principally affects the kidneys and often leads to acute dialysis, and in certain cases chronic kidney disease and death, primarily in children. Pursuant to the sale, Taro is acquiring all issued and outstanding shares of Thallion for a potential total consideration of CA$2.7 million, consisting of an upfront payment of CA$2.3 million and a potential future payment of CA$0.4 million contingent upon the completion of a pre-established milestone event, expected to occur within 24 months of the closing of the transaction. Additionally, BELLUS Health will receive a portion of certain post-approval revenues related to the Shigamab™ program. Story 5 In our feature story this week, on March 21st, the federal Liberal government officially presented their second budget since coming to power. In our feature story this week, on March 21st, the federal Liberal government officially presented their second budget since coming to power. In the months leading up to its release, this budget was of course billed by the Feds as the Innovation Budget, and certainly at first glance there are a few initiatives where spurring innovation or forming an Innovation Agenda for Canada is its goal.  But has this Budget measured up to its promise? Has the government truly delivered with Budget 2017 an Innovation Agenda to hitch our wagons to? We have with us today, Andrew Casey, CEO and president of BIOTECanada, the national organization that represents health care, agricultural, food, and research groups involved in biotechnology to find out if government has hit the mark or missed it in terms of delivering on its innovation mandate. Hello Andrew and welcome to the show. 1. Going into Budget 2017, there were many surveys, consultations and open dialogue between Government and industry, on what we wanted to see from this Innovation Agenda budget. Straight to point, did Budget 2017 live up to its hype? For BIOTECanada, what was on your wishlist- what were you hoping to see in the budget? What were the asks on the wish list that were answered, and which asks weren’t? Let’s look deeper, in our analysis of the investment summary, the biggest program of interest seems to be the $950 million “super clusters” fund, that will be an open competition in 2017 across six innovation industries, with biotech of course being one these industries. Like with most such initiatives there is of course some worry that biotech as one of the six, may not get it proverbial portion of the pie, does BIOTECanada see it this way, or do they feel that our industry can benefit from this fund? 5. In terms of strengthening science in government, Budget 2017 proposes to establish a new chief science advisor for Canada, what should we expect to see from the creation of this new role? There was also $6 million earmarked for stem cell research, and organizations in that field like the Stem Cell Foundation and other stakeholders seemed satisfied in that commitment, but on a grander scale, does that really compare with other leading jurisdictions in the field? Are those funds enough to capitalize on Canada’s strengths in this field? What we found interesting as well in Budget 2017 was the proposal of a new procurement program, called Innovative Solutions Canada, modeled on the SBIR (Small Business Innovation Research Program) in the U.S. with $50 million to go into this program. For comparison sake, in Fiscal Year 2016, the NIH’s SBIR and STTR programs south of the border will invest over $870 million into health and life science companies, so how does our commitment stack up? Is it a good first step into this arena? Glancing at the investment summary, we also noticed that basic research programs, such as the Tri-Councils, were not mentioned. Why do you think that was? Finally, another industry ask is always around supporting venture capital and Budget 2017 proposes $400 million over the next three years for a new Venture Capital Catalyst Initiative. Is this separate from the $400 million Venture Capital Action Plan from year’s past? Were there any other examples where existing funding and credits were maintained or even expanded upon in Budget 2017. Well Andrew, thank you for joining us today on our show and for your breakdown of #BUDGET2017, it’s always a pleasure for us to talk with you and get your insights on key industry topics.  

If someone said they could read your Past, Present and Future from ancient Sanskrit inscriptions written thousands of years ago on a dusty old palm leaf in a country you've never been to before, would you be skeptical? Well Andrew most certainly was - until he found out otherwise. Nothing prepared him for what the Naadi holy men told him that day - after all, he was supposed to be relaxing on holiday and nothing more. Yet a chance two hours with the Naadis changed all that forever!